Ascendis Pharma A/S Long-Term Debt | ASND

Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.

Main characteristics:

Term exceeds 12 months
Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
Repaid through regular payments (interest and/or principal) over several years

Why long-term debt is needed:

Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital.
Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks.
Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.

A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.

If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.

It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.

Examples of long-term debt:

Mortgage loans for property purchases
Corporate bonds issued by a company to raise capital
Project financing — long-term loans for building or expanding production facilities
Leasing obligations for equipment or transport

Annual Long-Term Debt Ascendis Pharma A/S

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	84.6 M	95.4 M	98 M	-	-	-	-	-	-	-	-	-	-

All numbers in EUR currency

Indicator range from annual reports

Maximum	Minimum	Average
98 M	84.6 M	92.7 M

Quarterly Long-Term Debt Ascendis Pharma A/S

2025-Q4	2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	84.6 M	84.6 M	84.6 M	84.6 M	90.1 M	-	-	95.4 M	-	-	-	98 M	95.6 M	94.1 M	89.6 M	85.1 M	27 M	29.1 M	30.8 M	30.7 M	31.5 M	31.5 M	13.2 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in EUR currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
98 M	13.2 M	65.5 M

Long-Term Debt of other stocks in the Biotechnology industry

Issuer	Long-Term Debt	Price	% 24h	Market Cap	Country
Praxis Precision Medicines PRAX	110 K	$ 346.47	2.63 %	$ 7.8 B	USA
Prelude Therapeutics Incorporated PRLD	15 M	$ 3.8	1.06 %	$ 292 M	USA
ProQR Therapeutics N.V. PRQR	9.55 M	$ 1.26	-3.82 %	$ 133 M	Niderland
Ocular Therapeutix OCUL	2.82 M	$ 6.66	0.68 %	$ 1.25 B	USA
PolyPid Ltd. PYPD	647 K	$ 6.56	3.96 %	$ 107 M	Israel
Outlook Therapeutics OTLK	189 K	$ 0.48	4.34 %	$ 16.7 M	USA
uniQure N.V. QURE	49.7 M	$ 24.64	8.5 %	$ 1.42 B	Niderland
Ultragenyx Pharmaceutical RARE	24 M	$ 16.7	3.44 %	$ 1.65 B	USA
Sarepta Therapeutics SRPT	829 M	$ 16.67	1.4 %	$ 1.67 B	USA
Rafael Holdings RFL	14.9 M	$ 1.12	4.67 %	$ 57.6 M	USA
REGENXBIO RGNX	65.2 M	$ 8.57	11.38 %	$ 442 M	USA
Rigel Pharmaceuticals RIGL	52.5 M	$ 44.17	0.58 %	$ 794 M	USA
SELLAS Life Sciences Group SLS	457 K	$ 8.41	0.5 %	$ 917 M	USA
Celsion Corporation CLSN	602 K	-	-6.63 %	$ 13.9 M	USA
I-Mab IMAB	23.1 M	-	-	$ 866 M	China
Tenax Therapeutics TENX	64.2 K	$ 1.7	0.3 %	$ 66.7 M	USA
Alexion Pharmaceuticals, Inc. ALXN	2.42 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	173 M	-	2.54 %	$ 160 B	France
Biophytis SA BPTS	1.83 M	-	-13.47 %	$ 169 M	France
CureVac N.V. CVAC	33.6 M	-	-	$ 867 M	Germany
BiondVax Pharmaceuticals Ltd. BVXV	124 M	-	0.74 %	$ 768 M	Israel
Abcam plc ABCM	95.8 M	-	-	$ 4.9 B	Britain
Rezolute RZLT	276 K	$ 4.09	1.74 %	$ 425 M	USA
Midatech Pharma plc MTP	4.76 M	-	-18.52 %	$ 27.3 M	Britain
Tiziana Life Sciences PLC TLSA	109 K	$ 0.62	1.33 %	$ 66.1 M	Britain
MorphoSys AG MOR	8.8 M	-	2.43 %	$ 254 M	Germany
Affimed N.V. AFMD	6.66 M	-	-34.95 %	$ 21.5 M	Germany
AnPac Bio-Medical Science Co., Ltd. ANPC	6.52 M	-	-1.58 %	$ 28.1 M	China
Celyad Oncology SA CYAD	118 K	-	-	$ 12.5 M	Belgium
Seer SEER	21.1 M	$ 1.61	-0.31 %	$ 88.9 M	USA
Gracell Biotechnologies GRCL	46.5 M	-	-	$ 3.37 B	China
Shattuck Labs STTK	1.58 M	$ 5.04	3.61 %	$ 351 M	USA
Silence Therapeutics plc SLN	93 K	$ 19.78	-0.05 %	$ 2.8 B	Britain
Stoke Therapeutics STOK	1.14 M	$ 27.75	1.98 %	$ 1.64 B	USA
Sutro Biopharma STRO	7.89 M	$ 10.25	0.79 %	$ 87.1 M	USA
Soligenix SNGX	244 K	$ 0.32	0.37 %	$ 1.66 M	USA
Teva Pharmaceutical Industries Limited TEVA	288 M	$ 43.19	1.85 %	$ 49.5 B	Israel
China SXT Pharmaceuticals SXTC	644 K	$ 2.96	2.78 %	$ 2.01 M	China
Spruce Biosciences SPRB	124 K	$ 46.52	-0.32 %	$ 35.7 M	USA
Takeda Pharmaceutical Company Limited TAK	4.51 T	$ 20.83	-0.38 %	$ 32.9 B	Japan
Supernus Pharmaceuticals SUPN	30.4 M	$ 29.29	1.88 %	$ 1.65 B	USA
Galapagos NV GLPG	5.19 M	-	-	$ 1.83 B	Belgium
Savara SVRA	29.9 M	$ 5.03	2.24 %	$ 1.12 B	USA
Teligent, Inc. TLGT	137 M	-	-13.85 %	$ 16.1 M	USA
TG Therapeutics TGTX	246 M	$ 65.76	2.33 %	$ 9.49 B	USA
Aphria Inc. APHA	400 M	-	-0.45 %	$ 4.87 B	Canada
Aerpio Pharmaceuticals, Inc. ARPO	125 K	-	-0.90 %	$ 104 M	USA
Chiasma, Inc. CHMA	1.68 M	-	-6.00 %	$ 238 M	USA